CT-322 v Avastin in NSCLC subjects taking Carbo/Taxol v1.0

• Research type

  Research Study

• Full title

  A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) with Non-Squamous Histology

• IRAS ID

  19558

• Sponsor organisation

  Bristol Myers Squibb International Corporation

• Eudract number

  2008-007768-41

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  NCT00850577

• Research summary

  N/A

• REC name

  London - Central Research Ethics Committee

• REC reference

  09/H0718/38

• Date of REC Opinion

  16 Oct 2009

• REC opinion

  Further Information Favourable Opinion